ELAHERE 5 mg/mL concentrate for solution for infusion
*Company:
AbbVie LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 22 August 2025
File name
PIL_Elahere 5mg-ml conc sol for infus_20Aug2025.pdf
Reasons for updating
- Change to Section 1 - what the product is
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 22 August 2025
File name
SmPC_Elahere 5mg-ml conc sol for infus_20Aug2025.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Editorial updates
Updated on 25 March 2025
File name
Elahere_PIL_MAA_Nov2024.pdf
Reasons for updating
- New PIL for new product
Updated on 25 March 2025
File name
Elahere_SmPC_MAA_Nov2024.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
AbbVie Limited
Address:
Citywest Business Campus, Dublin 24, IrelandTelephone:
+353 1 428 7900Fax:
+353 1 428 7940